Head-to-head · WeighScore
EmbraceRX vs FlyteHealth
The verdict
Too close to call — both grade 58.6/100 (C).
EmbraceRX and FlyteHealth land on the same WeighScore, so neither clears the other on our six graded dimensions. EmbraceRX sits one line higher on the board (#363 vs #364) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | EmbraceRX | FlyteHealth |
|---|---|---|
| WeighScore | 58.6/100 | 58.6/100 |
| Grade | C | C |
| Scorecard rank | #363 | #364 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #363 · C
Strengths
- Broad compounded GLP-1 menu — semaglutide (+B12), tirzepatide, oral semaglutide/tirzepatide capsules, plus Lipo-B
- Large peptide/longevity catalog (BPC-157, GHK-Cu, NAD+, MOTS-C) across injectable, oral, topical, and nasal formats
- Clinician-guided, compounded at FDA-registered pharmacies; partners with a licensed physician network (Samaritan MD)
- Full legal suite published (Terms, Privacy, HIPAA Notice, CCPA, Returns & Refunds)
Where it loses points
- Pricing not shown upfront — revealed only at checkout after a dose selection
- Offers investigational/research compounds (e.g., retatrutide, AOD-9604) that are not FDA-approved
- Compounding pharmacy partner not named ('FDA-registered pharmacies')
- Not LegitScript-certified (no certification displayed)
Graded #364 · C
Strengths
- Care led by board-certified obesity-medicine physicians
- Multidisciplinary team with NPs, dietitians, and care coordinators
- Published outcomes of about 13 to 16 percent weight loss over 12 months
- High GLP-1 medication adherence (around 86 percent in reported data)
- Comprehensive cardiometabolic care beyond GLP-1 alone
Where it loses points
- Distributed primarily via employers, payers, and health plans, not direct cash-pay
- Access is largely gated behind employer or plan sponsorship
- GLP-1 is prescribed only when appropriate, not guaranteed
- Self-pay pricing is not publicly listed (contact required)
- Less suited to consumers wanting fast direct-to-door GLP-1
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.